Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene (This gene does not contain this module)
	Known drug resistance mechanisms of this gene (This gene does not contain this module)
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor (This gene does not contain this module)
	Acts as a drug target< (This gene does not contain this module)

Gene: TXNIP

Summary for TXNIP

Gene information	Gene symbol	TXNIP
	Ensembl ID	ENSG00000265972
	Entrez ID	10628
	Gene name	thioredoxin interacting protein
	Synonyms	ARRDC6\|EST01027\|HHCPA78\|THIF\|VDUP1
	Gene type	protein_coding
	UniProtAcc	Q9H3M7

Top

Dataset with differentially expressed gene: TXNIP

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE138267	CDX	Tumor tissue	Lung cancer	Small cell lung cancer (SCLC)	Chemotherapy	NA	NA	Malignant cells	0.561054	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	B cells	0.390036	2.58e-43
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	CD8+ T cells	0.321251	7.04e-24
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	Mono/Macro	0.310416	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	NK cells	0.809744	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	B cells	0.912481	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	cDCs	0.51313	1.54e-10
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Mono/Macro	0.678699	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Plasma cells	0.859276	9.70e-10
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD8+ T cells	0.715987	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD4+ T cells	0.914721	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Mono/Macro	0.297715	3.55e-15
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD4+ T cells	0.305409	5.46e-25
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD8+ T cells	0.395772	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	B cells	0.414507	9.43e-17
GSE153697	patients	Bone marrow aspirate	Acute lymphoblastic leukemia	Relapsed B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	anti-CD19 CAR-T	NA	Mono/Macro	-1.6892	1.60e-06
GSE153697	patients	Bone marrow aspirate	Acute lymphoblastic leukemia	Relapsed B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	anti-CD19 CAR-T	NA	Malignant cells	-1.95608	0.00e+00
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD8+ T cells	0.772697	0.00e+00
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	Mono/Macro	0.336126	2.84e-29
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD4+ T cells	0.487459	0.00e+00
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	NK cells	0.496622	0.00e+00
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	B cells	0.892811	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	B cells	0.771227	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	NK cells	0.719159	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD4+ T cells	0.597856	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	Mono/Macro	0.635147	2.60e-37
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	post	CD4+ T cells	-0.413005	0.00e+00
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	post	Mono/Macro	-0.564261	0.00e+00
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	pre	NK cells	0.364274	0.00e+00
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	CD4+ T cells	-1.08797	6.04e-25
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	Mono/Macro	0.504202	1.01e-11
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	Erythrocytes	-0.477171	1.68e-20
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD4+ T cells	2.34438	0.00e+00
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD8+ T cells	1.92095	0.00e+00
GSE212217	patients	Peripheral blood mononuclear cells	Endometrial cancer	Epigenetic MMRd endometrial carcinoma	Immunotherapy	pembrolizumab	pre	Mono/Macro	-0.250223	0.00e+00
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Malignant cells	-0.757711	9.74e-05
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	B cells	1.21632	1.45e-31
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD8+ T cells	-0.410572	4.97e-23
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Neutrophils	0.579352	5.36e-12
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	post	CD4+ T cells	0.279684	0.00e+00
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	B cells	1.74462	1.78e-14
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	pDCs	-0.635852	6.61e-03
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Plasma cells	0.599405	5.86e-03
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD4+ T cells	0.324445	8.41e-07
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Neutrophils	-1.33692	0.00e+00
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Mono/Macro	-0.5243	3.40e-04
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	CD4+ T cells	0.514143	0.00e+00
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	B cells	0.684449	1.70e-16
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	Mono/Macro	0.63486	0.00e+00
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	CD8+ T cells	0.634944	0.00e+00
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	Malignant cells	1.28679	0.00e+00
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	NK cells	0.685324	0.00e+00
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	Mono/Macro	-0.489681	0.00e+00
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	NK cells	-0.437978	2.03e-20
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	Mono/Macro	-0.530014	9.34e-37
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	Malignant cells	-0.561456	5.94e-37
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	CD8+ T cells	-0.437516	0.00e+00
GSE161195	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	DARA-KRD (daratumumab + carfilzomib + lenalidomide + dexamethasone)	post	Malignant cells	-0.307033	5.02e-30
GSE158457	PDX cells	Cell line	Acute lymphoblastic leukemia	T-cell acute lymphoblastic leukemia (ALL)	Targeted therapy	dasatinib	NA	Malignant cells	0.331217	0.00e+00
GSE168668	LNCaP cell line	Cell line	Prostate cancer	Prostate cancer	Targeted therapy	enzalutamide	NA	Malignant cells	-0.671018	0.00e+00
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	cDCs	0.813241	2.27e-42
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	pre	Malignant cells	-1.28146	0.00e+00
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	pre	Erythrocytes	-1.18816	7.41e-05
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Erythrocytes	-0.305535	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD4+ T cells	0.404589	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	NK cells	0.602308	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	Erythrocytes	-1.14387	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	NK cells	-1.52145	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	B cells	-1.93579	3.70e-14
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	CD4+ T cells	-0.58323	9.28e-14
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	CD8+ T cells	-0.986356	2.23e-35
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	pre	CD8+ T cells	-0.303035	1.47e-03
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	pre	Malignant cells	-0.406634	0.00e+00
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	pre	CD4+ T cells	-0.614483	1.29e-03
GSE152469	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	NA	CD8+ T cells	-0.555806	6.80e-05
GSE131984_JQ1	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1	NA	Malignant cells	0.291657	5.45e-08
GSE131984_JQ1Pac	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1 + paclitaxel	NA	Malignant cells	0.702445	1.72e-27
GSE131984_Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	palbociclib	NA	Malignant cells	0.266479	4.06e-05
GSE108397	451Lu cell line	Cell line	Melanoma	Melanoma	Targeted therapy	PLX-4720	NA	Malignant cells	-0.451031	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	Malignant cells	0.544134	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	Malignant cells	-0.327315	3.95e-40
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	B cells	0.659945	4.20e-44
GSE175716	PDX	Tumor tissue	Liver cancer	Advanced hepatocellular carcinoma	Targeted therapy	sorafenib	NA	Malignant cells	0.758325	0.00e+00
GSE115251	Kelly cell line	Cell line	Neuroblastoma	Neuroblastoma	Targeted therapy	TAE684	NA	Malignant cells	-0.49557	0.00e+00
GSE164897_VemTra	A375 cell line	Cell line	Melanoma	B+E2:E57RAFV600E-mutant melanoma	Targeted therapy	vemurafenib + trametinib	NA	Malignant cells	1.60004	0.00e+00

Top

Expression of TXNIP in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to TXNIP

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Top

MicroRNAs (miRNA) regulating TXNIP

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
TXNIP	hsa-miR-20a-5p	99.1556	NM_001313972
TXNIP	hsa-miR-106b-5p	99.1556	NM_001313972
TXNIP	hsa-miR-526b-3p	99.0756	NM_001313972
TXNIP	hsa-miR-106a-5p	99.0756	NM_001313972
TXNIP	hsa-miR-302e	99.0643	NM_001313972
TXNIP	hsa-miR-20b-5p	98.8798	NM_001313972
TXNIP	hsa-miR-93-5p	98.8798	NM_001313972
TXNIP	hsa-miR-17-5p	98.8798	NM_001313972
TXNIP	hsa-miR-519d-3p	98.8798	NM_001313972
TXNIP	hsa-miR-520e-3p	98.3522	NM_001313972
TXNIP	hsa-miR-520a-3p	98.3522	NM_001313972
TXNIP	hsa-miR-373-3p	98.3522	NM_001313972
TXNIP	hsa-miR-520b-3p	98.3522	NM_001313972
TXNIP	hsa-miR-302b-3p	98.3522	NM_001313972
TXNIP	hsa-miR-302d-3p	98.3522	NM_001313972
TXNIP	hsa-miR-520d-3p	98.3522	NM_001313972
TXNIP	hsa-miR-520c-3p	98.3522	NM_001313972
TXNIP	hsa-miR-302c-3p	98.3522	NM_001313972
TXNIP	hsa-miR-372-3p	98.3522	NM_001313972
TXNIP	hsa-miR-302a-3p	98.3522	NM_001313972
TXNIP	hsa-miR-146a-3p	95.8079	NM_001313972
TXNIP	hsa-miR-6749-3p	95.0364	NM_001313972
TXNIP	hsa-miR-3085-3p	94.0606	NM_006472
TXNIP	hsa-miR-3064-5p	94.0606	NM_006472
TXNIP	hsa-miR-6504-5p	94.0606	NM_006472
TXNIP	hsa-miR-301b-5p	93.9218	NM_001313972
TXNIP	hsa-miR-301a-5p	93.9218	NM_001313972
TXNIP	hsa-miR-7155-5p	92.166	NM_006472
TXNIP	hsa-miR-593-3p	92.0975	NM_001313972
TXNIP	hsa-miR-3921	92.0627	NM_001313972
TXNIP	hsa-miR-4653-5p	92.0627	NM_001313972
TXNIP	hsa-miR-873-3p	91.5011	NM_001313972
TXNIP	hsa-miR-148b-3p	90.9835	NM_001313972
TXNIP	hsa-miR-548ah-5p	90.4942	NM_001313972
TXNIP	hsa-miR-3609	90.4942	NM_001313972
TXNIP	hsa-miR-3119	90.3833	NM_001313972
TXNIP	hsa-miR-152-3p	89.6653	NM_001313972
TXNIP	hsa-miR-148a-3p	89.6653	NM_001313972
TXNIP	hsa-miR-4796-3p	89.5969	NM_001313972
TXNIP	hsa-miR-216a-3p	88.4571	NM_001313972
TXNIP	hsa-miR-128-3p	88.4571	NM_001313972
TXNIP	hsa-miR-6881-5p	88.1595	NM_006472
TXNIP	hsa-miR-520g-3p	86.6871	NM_001313972
TXNIP	hsa-miR-520h	86.6871	NM_001313972
TXNIP	hsa-miR-3681-3p	86.1231	NM_001313972
TXNIP	hsa-miR-524-5p	85.7372	NM_001313972
TXNIP	hsa-miR-520d-5p	85.7372	NM_001313972
TXNIP	hsa-miR-8083	85.6261	NM_001313972
TXNIP	hsa-miR-1277-5p	85.4031	NM_001313972
TXNIP	hsa-miR-4701-5p	85.362	NM_001313972

Page: 1 2

Top

Motifs and transcription factors (TFs) regulating TXNIP

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
TXNIP	metacluster_174.3	MBD2; NFYA; NFYB; NFYC; PBX3 (directAnnotation).
TXNIP	metacluster_174.2	CEBPZ; CEBPZ; DRAP1; FOS; FOXI1; FOXI1; HMGXB3; IRF3; NFYA; NFYA; NFYA; NFYA; NFYA; NFYA; NFYA; NFYA; NFYA; NFYB; NFYB; NFYB; NFYB; NFYB; NFYC; NFYC; NFYC; NFYC; NFYC; NFYC; NFYC; PBX3; PBX3; SP2 (directAnnotation). NFYA; NFYA; NFYC; PBX1; PBX3 (inferredBy_Orthology).
TXNIP	metacluster_87.1	ZNF184 (directAnnotation).
TXNIP	yetfasco__TBP-TFIIA-TFIIB_1330	GTF2B; TBPL2 (inferredBy_Orthology).
TXNIP	transfac_pro__M06292	ZNF766 (directAnnotation).
TXNIP	transfac_pro__M04966	EP300 (directAnnotation).
TXNIP	hocomoco__ETS2_HUMAN.H11MO.0.B	ETS2 (directAnnotation).
TXNIP	jaspar__MA1954.1	FOXO1 (directAnnotation).
TXNIP	transfac_pro__M05392	SCRT2 (inferredBy_Orthology).
TXNIP	metacluster_168.4	ZNF652 (directAnnotation).
TXNIP	jaspar__MA1946.1	FOXI1 (directAnnotation).
TXNIP	transfac_pro__M07420	HES1 (directAnnotation).
TXNIP	jaspar__MA1953.1	FOXO1 (directAnnotation).
TXNIP	taipale_tf_pairs__GCM1_MAX_NNCACGTGNNNGCGGGYN_CAP_repr	GCM1; MAX (directAnnotation).
TXNIP	transfac_pro__M05464	SALL1 (directAnnotation).
TXNIP	jaspar__MA1956.1	FOXO1 (directAnnotation).
TXNIP	metacluster_140.7	NR2E1; NR2E3 (directAnnotation). NR2E1; NR2E1; NR2E1 (inferredBy_Orthology).
TXNIP	jaspar__MA1935.1	FOXI1 (directAnnotation).
TXNIP	transfac_pro__M06646	ZNF607 (directAnnotation).
TXNIP	transfac_pro__M04860	RXRA (directAnnotation).
TXNIP	transfac_pro__M06552	ZNF420 (directAnnotation).
TXNIP	tfdimers__MD00302	IRF7; IRF8 (directAnnotation).
TXNIP	metacluster_172.19	HMGA2 (directAnnotation).
TXNIP	cisbp__M01113	SOHLH2 (directAnnotation).
TXNIP	taipale_tf_pairs__FOXO1_ETV4_RWMAACAGGAARNN_CAP	ETV4; FOXO1 (directAnnotation).
TXNIP	tfdimers__MD00186	NFATC3; SPI1 (directAnnotation).
TXNIP	transfac_pro__M01279	IRF3 (directAnnotation).
TXNIP	metacluster_71.1	ARNT (directAnnotation).
TXNIP	hocomoco__PRGR_HUMAN.H11MO.1.A	PGR (directAnnotation).
TXNIP	transfac_pro__M12614	HEY1 (directAnnotation).
TXNIP	transfac_pro__M00921	NR3C1 (directAnnotation).
TXNIP	swissregulon__mm__Atf2	ATF2 (inferredBy_Orthology).
TXNIP	tfdimers__MD00399	ELF5; NFATC3 (directAnnotation).
TXNIP	transfac_pro__M07284	ERG (directAnnotation).
TXNIP	hocomoco__NFAT5_HUMAN.H11MO.0.D	NFAT5 (directAnnotation).
TXNIP	metacluster_167.2	BCL11A; BCL11A; BCL11A; EP300; IKZF2; IKZF2; IRF4; IRF4; IRF4; IRF8; PRDM1; SPI1; TBL1XR1; ZBED1; ZNF41 (directAnnotation). IKZF1; IRF4; IRF4; SPI1 (inferredBy_Orthology).
TXNIP	metacluster_190.7	ILF2; NFATC1; NFATC1; NFATC1; NFATC1; NFATC2; NFATC2; NFATC2; NFATC3; NFATC3; NFATC3; NFATC3; NFATC4; NFATC4; NFATC4 (directAnnotation).
TXNIP	transfac_pro__M01281	ILF2; NFATC2 (directAnnotation).
TXNIP	hdpi__RAN	RAN (directAnnotation).
TXNIP	transfac_pro__M03555	ILF2; NFATC2 (directAnnotation).
TXNIP	tfdimers__MD00089	STAT6 (directAnnotation).
TXNIP	swissregulon__hs__NFATC2	NFATC2 (directAnnotation).
TXNIP	transfac_pro__M07608	ILF2; NFAT5; NFATC1; NFATC2; NFATC4 (directAnnotation).
TXNIP	transfac_pro__M01886	NFATC3 (directAnnotation).
TXNIP	hocomoco__NFAC2_MOUSE.H11MO.1.C	NFATC2 (inferredBy_Orthology).
TXNIP	tfdimers__MD00044	ELF1; ELF2; ELF4; ELK1; ELK3; ELK4; ERG; ETS1; ETS2; ETV4; ETV6; ETV7; FLI1; GABPA; GABPB1; SIRT6; SPI1; SPIB (directAnnotation).
TXNIP	transfac_pro__M07607	NFATC3 (directAnnotation).
TXNIP	c2h2_zfs__M0369	BCL6B (inferredBy_Orthology).
TXNIP	hocomoco__PRDM6_HUMAN.H11MO.0.C	PRDM6 (directAnnotation).
TXNIP	transfac_pro__M07301	NFATC4 (directAnnotation).

Page: 1 2 3 4 5 6

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."